Wegovy
-
healthPrice Wars Reshape US Weight-Loss Drug Market
Eli Lilly and rivals slash prices amid fierce competition, pushing direct-to-consumer models while millions still lack insurance coverage.
-
healthGLP-1 Drugs Linked to Improved Mental Health in New Study
A large Swedish study finds semaglutide and liraglutide tied to lower risks of worsening anxiety, depression, and substance use disorders.
-
healthGLP-1 Drugs Show Heart Attack Recovery Potential
New research reveals Ozempic-like drugs may reduce heart damage after a heart attack by restoring blood flow through capillaries, offering a promising new therapeutic pathway.
-
healthGLP-1 Users Regain Minimal Weight After Stopping, Real-World Study Finds
A Cleveland Clinic study shows most patients regain only 0.5% of lost weight a year after stopping Ozempic or similar GLP-1 drugs.
-
healthIndia's Generic Semaglutide Surge Could Reshape Global Obesity Treatment
With Novo Nordisk's semaglutide patent expiring in India, domestic manufacturers are preparing dozens of affordable generics, potentially slashing costs and expanding access to GLP-1 weight-loss drugs worldwide.
-
healthOzempic Users Keep Off 25% of Lost Weight After Stopping
New study reveals weight regain patterns after discontinuing GLP-1 drugs like Ozempic and Wegovy, raising concerns over muscle loss and long-term health.
-
healthFDA Cites Novo Nordisk for Failing to Report Patient Deaths Linked to GLP-1 Drugs
The FDA issued a warning letter accusing Novo Nordisk of systemic failures in reporting serious side effects-including deaths-of patients using Ozempic and Wegovy.
-
healthLondon's Weight Loss Drug Gap Fuels Dangerous Private Market
Slow NHS rollout leaves half a million eligible Londoners seeking risky private or counterfeit obesity treatments.